Exagen Inc. (XGN)
NASDAQ: XGN · Real-Time Price · USD
3.350
+0.020 (0.60%)
Mar 13, 2025, 4:00 PM EDT - Market closed
Exagen Revenue
In the year 2024, Exagen had annual revenue of $55.64M with 5.89% growth. Exagen had revenue of $13.66M in the quarter ending December 31, 2024, a decrease of -0.80%.
Revenue (ttm)
$55.64M
Revenue Growth
+5.89%
P/S Ratio
1.10
Revenue / Employee
$310,844
Employees
179
Market Cap
59.10M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 55.64M | 3.09M | 5.89% |
Dec 31, 2023 | 52.55M | 6.99M | 15.33% |
Dec 31, 2022 | 45.56M | -2.74M | -5.66% |
Dec 31, 2021 | 48.30M | 6.32M | 15.07% |
Dec 31, 2020 | 41.98M | 1.59M | 3.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
XGN News
- 2 days ago - Exagen Inc. (XGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights - GlobeNewsWire
- 16 days ago - Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025 - GlobeNewsWire
- 5 weeks ago - Exagen Inc. to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results - GlobeNewsWire
- 3 months ago - Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD - GlobeNewsWire
- 4 months ago - Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform - GlobeNewsWire
- 4 months ago - Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript - Seeking Alpha